Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma.
Thorel L, Morice PM, Paysant H, Florent R, Babin G, Thomine C, Perréard M, Abeilard E, Giffard F, Brotin E, Denoyelle C, Villenet C, Sebda S, Briand M, Joly F, Dolivet E, Goux D, Blanc-Fournier C, Jeanne C, Villedieu M, Meryet-Figuiere M, Figeac M, Poulain L, Weiswald LB. Thorel L, et al. Among authors: abeilard e. J Exp Clin Cancer Res. 2023 Oct 7;42(1):260. doi: 10.1186/s13046-023-02809-8. J Exp Clin Cancer Res. 2023. PMID: 37803448 Free PMC article.
Functional miRNA Screening Identifies Wide-ranging Antitumor Properties of miR-3622b-5p and Reveals a New Therapeutic Combination Strategy in Ovarian Tumor Organoids.
Vernon M, Lambert B, Meryet-Figuière M, Brotin E, Weiswald LB, Paysant H, Vigneron N, Wambecke A, Abeilard E, Giffard F, Louis MH, Blanc-Fournier C, Gauduchon P, Poulain L, Denoyelle C. Vernon M, et al. Among authors: abeilard e. Mol Cancer Ther. 2020 Jul;19(7):1506-1519. doi: 10.1158/1535-7163.MCT-19-0510. Epub 2020 May 5. Mol Cancer Ther. 2020. PMID: 32371581
The lncRNA 'UCA1' modulates the response to chemotherapy of ovarian cancer through direct binding to miR-27a-5p and control of UBE2N levels.
Wambecke A, Ahmad M, Morice PM, Lambert B, Weiswald LB, Vernon M, Vigneron N, Abeilard E, Brotin E, Figeac M, Gauduchon P, Poulain L, Denoyelle C, Meryet-Figuiere M. Wambecke A, et al. Among authors: abeilard e. Mol Oncol. 2021 Dec;15(12):3659-3678. doi: 10.1002/1878-0261.13045. Epub 2021 Jul 13. Mol Oncol. 2021. PMID: 34160887 Free PMC article.
PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
Jebahi A, Villedieu M, Pétigny-Lechartier C, Brotin E, Louis MH, Abeilard E, Giffard F, Guercio M, Briand M, Gauduchon P, Lheureux S, Poulain L. Jebahi A, et al. Among authors: abeilard e. Cancer Lett. 2014 Jun 28;348(1-2):38-49. doi: 10.1016/j.canlet.2014.03.001. Epub 2014 Mar 18. Cancer Lett. 2014. PMID: 24650799 Free article.
Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
Lheureux S, N'Diaye M, Blanc-Fournier C, Dugué AE, Clarisse B, Dutoit S, Giffard F, Abeilard E, Briand M, Labiche A, Grellard JM, Crouet H, Martin S, Joly F, Poulain L. Lheureux S, et al. Among authors: abeilard e. Int J Cancer. 2015 Mar 1;136(5):E340-50. doi: 10.1002/ijc.29104. Epub 2014 Aug 8. Int J Cancer. 2015. PMID: 25066666
17 results